Immuneering plans to evaluate IMM-1-104 in combination with Libtayo in patients with advanced non-small cell lung cancer in its ongoing Phase ...
This was the stock's second consecutive day of gains.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback